ABC | Volume 113, Nº6, Dezembro 2019

Artigo Original Barbosa et al Nrf2, NF- κ B e PPAR β / δ em pacientes com DAC Arq Bras Cardiol. 2019; 113(6):1121-1127 1. Pinho RA, AraújoMC, Ghisi GL, Benetti M. Coronary heart disease, physical exercise and oxidative stress. Arq Bras Cardiol. 2010;94(4):549–55. 2. GoAS, MozaffarianD, Roger VL, Benjamin EJ, Berry JD, BlahaMJ, et al. Heart disease and stroke statistics--2014 update: a report from the AmericanHeart Association. Circulation. 2014;129(3):e28–292. 3. Mack M, Gopal A. Epidemiology, Traditional and Novel Risk Factors in Coronary Artery Disease. Heart Fail Clin. 2016;12(1):1–10. 4. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480–6. 5. GomesF,TeloDF,SouzaHP,Nicolau JC,HalpernA,Serrano JrCV.Obesidade e doença arterial coronariana: papel da inflamação vascular. Arq Bras Cardiol. 2010;94(2):273–9. 6. Mehta D. Integrative Medicine and Cardiovascular Disorders. Prim Care. 2017;44(2):351–67. 7. Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84(4):1381–478. 8. Herrmann J, Lerman A. The endothelium: dysfunction and beyond. J Nucl Cardiol. 2001;8(2):197–206. 9. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25(1):29–38. 10. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol. 2004;24(5):469–73. 11. Stefanson AL, Bakovic M. Dietary regulation of Keap1/Nrf2/ARE pathway: focus on plant-derived compounds and trace minerals. Nutrients. 2014;6(9):3777–801. 12. Aminzadeh MA, Nicholas SB, Norris KC, Vaziri ND. Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2013;28(8):2038–45. 13. Singh S, Vrishni S, Singh BK, Rahman I, Kakkar P. Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radic Res. 2010;44(11):1267–88. 14. Pall ML, Levine S. Nrf2, a master regulator of detoxification and also antioxidant, anti-inflammatory and other cytoprotective mechanisms, is raised by health promoting factors. Sheng Li Xue Bao. 2015;67(1):1–18. 15. Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Ren Physiol. 2010;298(3):F662–71. 16. Toral M, RomeroM, Pérez-Vizcaíno F, Duarte J, Jiménez R. Antihypertensive effects of peroxisome proliferator-activated receptor- β / δ activation. Am J Physiol Heart Circ Physiol. 2017;312(2):H189–200. 17. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, et al. Cardiomyocyte- restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med. 2004;10(11):1245–50. 18. Zarzuelo MJ, Jiménez R, Galindo P, Sánchez M, Nieto A, Romero M, et al. Antihypertensive effects of peroxisome proliferator-activated receptor- β activation in spontaneously hypertensive rats. Hypertension. 2011;58(4):733–43. 19. Quintela AM, Jiménez R, Gómez-Guzmán M, Zarzuelo MJ, Galindo P, Sánchez M, et al. Activation of peroxisome proliferator-activated receptor- β /- δ (PPAR β / δ ) prevents endothelial dysfunction in type 1 diabetic rats. Free Radic Biol Med. 2012;53(4):730–41. 20. Toral M, Gómez-Guzmán M, Jiménez R, Romero M, Zarzuelo MJ, Utrilla MP, et al. Chronic peroxisome proliferator-activated receptor β / δ agonist GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity. J Hypertens. 2015;33(9):1831–44. 21. Palomer X, Barroso E, Pizarro-Delgado J, Peña L, Botteri G, Zarei M, et al. PPAR β / δ : A Key Therapeutic Target in Metabolic Disorders. Int J Mol Sci. 2018;19(3). pii:E913. 22. Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis. 1972;25(6):329–43. 23. Malachias MV, Plavnik FL, Machado CA, Malta D, Scala LC, Fuchs S, et al. 7th Brazilian Guideline of Arterial Hypertension: Chapter 1 - Concept, Epidemiology and Primary Prevention. Arq Bras Cardiol. 2016;107(3):1–6. 24. FriedewaldWT, Levy RI, FredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502. 25. Cardozo LFMF, Stockler-Pinto MB, Mafra D. Brazil nut consumption modulates Nrf2 expression in hemodialysis patients: A pilot study. Mol Nutr Food Res. 2016;60(7):1719–24. 26. Pedruzzi LM, Cardozo LF, Daleprane JB, Stockler-Pinto MB, Monteiro EB, Leite M Jr, et al. Systemic inflammation and oxidative stress in hemodialysis patients are associated with down-regulation of Nrf2. J Nephrol. 2015;28(4):495-501. 27. Mozzini C, Fratta Pasini A, Garbin U, Stranieri C, Pasini A, Vallerio P, et al. Increased endoplasmic reticulum stress and Nrf2 repression in peripheral bloodmononuclear cells of patients with stable coronary artery disease. Free Radic Biol Med. 2014 Mar;68:178–85. 28. Visvikis-Siest S, Marteau J-B, Samara A, Berrahmoune H, Marie B, Pfister M. Peripheral bloodmononuclear cells (PBMCs): a possiblemodel for studying cardiovascular biology systems. Clin ChemLabMed. 2007;45(9):1154–68. 29. Li C, Browder W, Kao RL. Early activation of transcription factor NF- kappaB during ischemia in perfused rat heart. Am J Physiol. 1999;276(2 Pt 2):H543–552. 30. Wilson SH, Best PJM, Edwards WD, Holmes DR, Carlson PJ, Celermajer DS, et al. Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis. 2002;160(1):147–53. 31. Gareus R, Kotsaki E, Xanthoulea S, van der Made I, Gijbels MJJ, Kardakaris R, et al. Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell Metab. 2008;8(5):372–83. 32. Malhotra D, Thimmulappa R, Navas-Acien A, Sandford A, Elliott M, Singh A, et al. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med. 2008;178(6):592–604. 33. Suzuki M, Betsuyaku T, Ito Y, Nagai K, Nasuhara Y, Kaga K, et al. Down- regulatedNF-E2-related factor2 inpulmonarymacrophagesofagedsmokers and patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2008;39(6):673–82. 34. ZhuH, Jia Z, Zhang L, YamamotoM, Misra HP, TrushMA, et al. Antioxidants and phase 2 enzymes in macrophages: regulation by Nrf2 signaling and protection against oxidative and electrophilic stress. Exp Biol Med (Maywood). 2008;233(4):463–74. 35. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. ’United States Renal Data System2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis. 2012;59(1 Suppl 1):A7, e1–420. Referências 1126